Bacterial vaccines in development 1

Published on September 30, 2015   20 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

DR. KATHRIN U. JANSEN: Hello. My name is Kathrin Jansen. I'm a Senior Vice President at Pfizer, responsible for vaccine research and development. Today, I will discuss bacterial vaccines in development.
Today's lecture is intended to give you a brief overview of licensed bacterial vaccines, and some examples of bacterial vaccines in development, to discuss key principles of bacterial vaccine design and development, to share with you some insights in the R&D efforts to develop bacterial vaccines. And I will be using three examples. The examples I have chosen are programs that my colleagues and I are working on at Pfizer. So they are real life examples of bacterial vaccine development. Specifically, we will touch on vaccines in development to protect against toxin-mediated diseases. The example is Clostridium difficile. We will touch on vaccines in development to protect against a very complex organism. The example is staphylococcus aureus, where the disease is mediated by the bacterium itself, and the virulence factors that it expresses. And finally, we will discuss recently licenced vaccines to protect the gram-negative bacterium, Neisseria meningitidis serogroup B.